Surgeons in China reported the transplant of a genetically modified pig liver segment into a patient with advanced liver tumor; the graft functioned and supported metabolic activity for 38 days before removal due to thrombotic microangiopathy. The case, published in the Journal of Hepatology, showed the xenograft produced bile, albumin and clotting factors while stabilizing the patient’s vitals. The team treated immune activation with immunosuppression and plasma exchange, then explanted the graft when clotting complications worsened; the patient survived an additional 133 days before dying of gastrointestinal bleeding. Authors and commentators framed the procedure as proof‑of‑principle for xenogeneic organs providing temporary physiological support.